New drug for hypoparathyroidism

Amolyt Pharma is a peptide designed to selectively target a specific configuration of the parathyroid hormone receptor protein. It ensures the normalization of calcium levels with the subsequent elimination of the manifestations of hypoparathyroidism with a fairly high safety profile. By stimulating the reabsorption of calcium in the kidneys, the selective action of AZT-3601 provides limited excretion of calcium in the urine. This prevents the development of chronic kidney disease.

In this trial, AZT-3601 tolerability, pharmacodynamics, pharmacokinetics and efficacy after use in a sample of healthy volunteers and people with hypoparathyroidism will be tested. The first one of 130 participants has already started receiving therapy. Also, in addition to AZT-3601, many manufacturers will develop several analogs of parathyroid hormone in different forms. Their main purpose is to provide a more lasting effect of the drug molecule.

Source: HEALIO